Pimozide - Generic Drug Details

What are the generic drug sources for pimozide and what is the scope of freedom to operate?

Pimozide is the generic ingredient in two branded drugs marketed by Teva and Ph Health, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for pimozide. One supplier is listed for this compound.

Summary for pimozide

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	21
Patent Applications:	7,100
Drug Prices:	Drug price trends for pimozide
What excipients (inactive ingredients) are in pimozide?	pimozide excipients list
DailyMed Link:	pimozide at DailyMed

See drug prices for pimozide

Recent Clinical Trials for pimozide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1
Applied Biology, Inc.	N/A

See all pimozide clinical trials

Pharmacology for pimozide

Drug Class

Typical Antipsychotic

Medical Subject Heading (MeSH) Categories for pimozide

Anti-Dyskinesia Agents

Antipsychotic Agents

Dopamine Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for pimozide

N05AG	Diphenylbutylpiperidine derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for pimozide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	ORAP	pimozide	TABLET;ORAL	017473-003	Aug 27, 1997		DISCN	Yes	No
Ph Health	PIMOZIDE	pimozide	TABLET;ORAL	204521-002	Sep 28, 2015		RX	No	Yes
Teva	ORAP	pimozide	TABLET;ORAL	017473-001	Jul 31, 1984		DISCN	Yes	No

Pimozide Market Analysis and Financial Projection

Last updated: February 6, 2026

What Are the Market Dynamics for Pimozide?

Pimozide is an antipsychotic drug primarily used to manage Tourette's syndrome and, less frequently, schizophrenia. Its market presence is shaped by clinical guidelines, regulatory status, and competition.

Therapeutic Use and Clinical Guidelines

• Approved indications are limited to Tourette's disorder and certain psychotic conditions.
• Prescribed mainly in the United States and select European countries.
• Usage declines with the emergence of newer atypical antipsychotics and increased safety concerns, especially regarding cardiac side effects.

Competitive Landscape

• Pimozide faces competition from atypical antipsychotics like risperidone, aripiprazole, and olanzapine.
• These alternatives provide similar efficacy with fewer side effects and have broader FDA approval for multiple indications.
• Pimozide's off-label use persists in some cases but is limited by safety warnings.

Regulatory Environment

• FDA labeling restricts pimozide's use due to risks of QT prolongation and torsades de pointes.
• Some European regulators have similar restrictions or withdrawn approval for certain indications.
• No recent new market approvals or expanded indications noted since the early 2000s.

Market Size and Trends

• The global antipsychotic market was valued at approximately $14 billion in 2022.
• Pimozide's share remains small, estimated below $50 million annually, owing to limited approved uses.
• Market decline is projected as newer drugs replace pimozide in clinical practice.

What Is the Financial Trajectory of Pimozide?

Revenue Trends

• Revenue remains stable but flat, primarily from legacy prescriptions.
• Low sales volumes restrict revenue growth prospects.
• Patent protection has long expired; no exclusivity periods influence the market.

Manufacturing and Supply Chain

• Manufactured by a handful of generic producers.
• Production costs are low due to generic manufacturing, but sales volume limits profit margins.
• Supply chain disruptions are minimal, given mature manufacturing processes.

Investment and R&D Outlook

• Minimal R&D investment due to lack of new indications or formulations.
• No pipeline activity from major companies on pimozide-specific development.
• Future market value hinges on continued off-label prescribing and market acceptance for niche uses.

Pricing Trends

• Pricing is based on generic market standards.
• No significant price increases observed in recent years.
• Price competition among generic suppliers maintains low cost for healthcare systems.

How Do External Factors Affect Pimozide’s Market and Finance?

Safety Concerns and Regulatory Warnings

• QT prolongation risk leads to black box warnings.
• Regulatory warnings limit prescribing flexibility; potential lawsuits pose financial risks.
• Ongoing safety monitoring may further restrict use.

Market Shifts Toward Atypical Antipsychotics

• Shift in prescribing patterns favors drugs with better safety profiles.
• Pimozide's market share diminishes as clinical practice favors newer agents.

Legal and Reimbursement Factors

• Pimozide's reimbursement rates are standard but constrained by its limited indication.
• Insurance coverage aligns with current guidelines, restricting off-label use.

Impact of Patent and Exclusivity Status

• No patent protection remains; generics dominate.
• Market entry barriers are low, fostering competition and suppressing prices.

Key Takeaways

• Pimozide's restricted use and safety profile limit market growth.
• Competition from newer atypical antipsychotics drives decline in prescriptions.
• Revenue remains stable but does not show growth prospects.
• External safety concerns and regulatory restrictions exert ongoing pressure.
• The future trajectory depends on niche utilization and off-label prescribing patterns.

FAQs

1. Is pimozide still approved for any new indications?
No. Regulatory agencies have not approved new indications recently. The drug's use remains limited to specific approved conditions with safety considerations.

2. What are the main safety issues associated with pimozide?
The primary concern is QT prolongation, which can lead to torsades de pointes, a potentially fatal arrhythmia. This safety profile restricts its use in vulnerable populations.

3. Are there any new formulations or delivery methods for pimozide?
No, there are no recent developments in formulations or delivery methods; the market relies mainly on existing oral tablet forms.

4. How does pimozide compare financially to newer antipsychotics?
Pimozide generates significantly less revenue due to limited indications and safety warnings, whereas newer atypicals generate hundreds of millions in global sales.

5. What is the outlook for generics manufacturers producing pimozide?
Manufacturers will continue to supply pimozide as a low-cost option, but their market share and profits are limited by declining prescription volume.

---

Sources:

[1] IQVIA, "Global Psychotropic Medications Market," 2022.
[2] U.S. Food and Drug Administration, "Pimozide Label," 2021.
[3] EvaluatePharma, "Antipsychotics Market Analysis," 2022.
[4] WHO, "Regulatory Status of Pimozide," 2020.